Takeda has moved its potential first-in-class diabetes candidate TAK-875 into phase III clinical trials. The company hopes TAK-875 will offer …
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
How will biomarker-led diagnostics reshape respiratory medicine?

